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Abstract
Background Two pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potential drug–drug interaction 
between elagolix, an oral gonadotropin-releasing hormone receptor antagonist, and an oral contraceptive (ethinylestradiol 
[EE] 0.035 mg and norgestimate 0.18/0.215/0.25 mg) or progestin-only contraceptive (norethindrone 0.35 mg) in healthy 
premenopausal women.
Methods These phase I studies used a two-period, sequential design, where period 1 included treatment with oral contracep-
tives, followed by period 2 with contraceptives coadministered with elagolix 150 mg once daily.
Results In study 1, pharmacokinetic exposures for EE in period 2 increased by 30% and the norgestimate metabolites 
decreased by approximately 15% when coadministered with elagolix. Mean hormone exposure appeared lower for follicle-
stimulating hormone (FSH; 31%), luteinizing hormone (LH; 38%), and estradiol (E2; 16%). The percentage of women with 
consecutive progesterone (P) concentrations above 5 nmol/L was similar in both periods. Norethindrone pharmacokinetic 
exposures were comparable in both periods. The hormone exposure for LH and FSH was similar, and mean E2 exposure 
was 32% lower in period 2. The percentage of subjects with consecutive ovulatory P concentrations was also similar in both 
periods (study 2). Safety and tolerability profiles were unremarkable in both studies.
Conclusions Coadministration of elagolix 150 mg once daily with oral contraceptives containing EE and norgestimate, or 
norethindrone, resulted in small pharmacokinetic changes in the oral contraceptive components. Similar or lower FSH, LH, 
and E2 exposures were observed during coadministration, with ovulatory P concentrations also comparable in both periods. 
The pharmacodynamic profiles of the oral contraceptives were maintained when coadministered with elagolix.
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1 Introduction
Elagolix, a novel, non-peptide, oral, short-acting competi-
tive gonadotropin-releasing hormone receptor antagonist, 
was approved by the US FDA in 2018 for the management 
of moderate-to-severe pain associated with endometriosis 
[1]. Treatment with elagolix in women with endometriosis-
associated pain has provided benefits with reductions in 
dysmenorrhea, non-menstrual pelvic pain, and dyspareunia 
[2], as well as improvements in workplace and household 
productivity [3, 4]. Elagolix pharmacokinetic (PK) and 
pharmacodynamic (PD) studies have shown dose-dependent 
suppression of luteinizing hormone (LH) and follicle-stimu-
lating hormone (FSH), estradiol (E2), and progesterone (P), 
as well as suppression of ovulation [5–8].
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Key Points 
Small changes in the pharmacokinetics of oral con-
traceptives were observed when coadministered with 
elagolix 150 mg once daily.
Based on the assessments of luteinizing hormone, 
follicle-stimulating hormone, estradiol, and ovulatory 
progesterone concentrations, the coadministration of oral 
contraceptives with elagolix 150 mg once daily does not 
appear to lessen the hormone pharmacodynamics of the 
oral contraceptives.
with healthy premenopausal women (Fig. 1). In study 1, all 
women received COC pills with doses of ethinylestradiol 
(EE; 0.035 mg) and norgestimate (0.18/0.215/0.25 mg) for 
≥ 3 months prior to study start (day 1). Period 1 consisted of 
28 days of women continuing their existing regimen. During 
period 2 (days 29–84), women received a COC and elagolix 
150 mg tablet once daily; this elagolix dose was one of the 
doses (150 mg once daily and 200 mg twice daily) evaluated 
in phase III trials. In study 2, women received a norethin-
drone 0.35 mg tablet once daily (a progestin-only contracep-
tive) for period 1; those who were naïve to the mini-pill had 
a 1-month lead-in. The same treatment pattern was followed 
as in study 1.
Women self-administered the study drug(s) throughout 
the treatment period. At each visit, women were counseled 
on medication adherence and appropriate and effective use 
of dual non-hormonal contraception. Women were followed 
until the resumption of menses or 60 days, whichever came 
first.
2.2  Inclusion/Exclusion Criteria
The following criteria apply to both studies. Subjects were 
required to be healthy premenopausal females aged between 
18 and 49 years, inclusive; have a history of regular men-
strual cycles prior to initial study drug administration; have 
a negative serum and urine pregnancy test; body mass index 
(BMI) 18–35 kg/m2; and in general good health based on 
the results of a medical history, physical examination, vital 
signs, laboratory profile, and 12-lead electrocardiogram.
Subjects were excluded if they were < 6 months post-
partum, post-abortion, post-pregnancy, or post-lactation; 
pregnant or breast feeding; were using hormonal medication 
other than the specified oral contraceptive; were using any 
known inhibitors or inducers of cytochrome P450 enzyme 
3A (CYP3A), P-glycoprotein (P-gp) inhibitors within 1 
month prior; and had a history of ovarian cysts, polycystic 
ovarian syndrome, oophorectomy, or hysterectomy. The hor-
monal therapies, known inducers/inhibitors of CYP3A, and 
inhibitors of P-gp were not to be taken during the screening, 
treatment, or follow-up periods of either study.
2.3  Pharmacokinetic/Pharmacodynamic Sampling
For intensive 24-h PK sampling for both studies, women 
remained at the study site during period 1 (oral contracep-
tives alone) and period 2 (oral contraceptives + elagolix). 
Blood samples for PK analysis {EE, metabolites of norg-
estimate (norelgestromin [NGMN], norgestrel [NG]), nore-
thindrone, elagolix} were collected by venipuncture at the 
following time points: prior to dosing, and 0.5, 1, 1.5, 2, 
3, 4, 6, 8, 10, 12, 16, and 24 h after dosing (days indicated 
in Fig. 1). The steady-state PK sampling of norgestimate 
Elagolix is not a contraceptive and effective methods of 
birth control should be used while taking elagolix. In addi-
tion, the elagolix product label states that its efficacy may be 
reduced in women taking estrogen-containing contraceptives 
[1]. As women are still looking for effective birth control 
options while receiving treatment for endometriosis, it is 
important to evaluate whether elagolix may be coadminis-
tered with hormonal contraceptives from a PK/PD and toler-
ability perspective.
Combination oral contraceptives (COCs) and progestin-
only (mini-pill) contraceptives are two effective means of 
hormonal contraception and are options for women treated 
with elagolix. The main mechanism for these hormonal 
contraceptives is to inhibit ovulation through inhibiting the 
pituitary production and secretion of FSH and LH [9]. Two 
studies were conducted to evaluate the potential drug–drug 
interaction (DDI) between elagolix and COCs or the mini-
pill and the impact of coadministration with elagolix on PK 
and PD, as well as the effects on safety and tolerability.
2  Methods
The studies were conducted in accordance with the protocol 
and guidelines governing clinical study conduct and ethical 
principles that have their origin in the Declaration of Hel-
sinki. Institutional Review Board approval was obtained 
at each of the five sites (Schulman Associates IRB, Inc., 
Cincinnati, OH, USA). All women signed informed consent 
forms before participating.
2.1  Study Design
Two separate phase I, multiple-dose, open-label studies 
were conducted according to a two-period, sequential design 
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metabolites were taken when a norgestimate dose of 0.25 
mg was administered in both periods.
Blood samples for PD analysis (FSH, LH, E2, and P) 
were collected by venipuncture once weekly for study 1 and 
twice weekly on non-consecutive days for study 2. During 
intensive PK days, PD samples were collected predose and 
24 h after dosing.
Samples quantified below the lowest standard were 
reported as zero.
2.3.1  Pharmacokinetic Sample Analysis
EE, metabolites of norgestimate, norethindrone, and elagolix 
blood samples were collected in potassium (K2) ethylenedi-
aminetetraacetic acid (EDTA)-containing collection tubes. 
The blood samples were centrifuged using a refrigerated 
centrifuge (1100–1300 g for approximately 10 min) within 
60 min of collection to separate the plasma. The plasma 
samples were placed in the freezer within 2 h after collection 
and maintained at − 70 °C until shipped to AbbVie.
The elagolix, EE, NGMN, and NG plasma assays were 
performed by the Drug Analysis Department of AbbVie, 
North Chicago, IL, USA. Plasma concentrations of EE, 
NGMN, NG, norethindrone, and elagolix [5] were deter-
mined using a validated liquid chromatography method 
with tandem mass spectrometric detection (LC–MS/MS). 
The samples were analyzed by subject. The lower limits of 
quantitation (LLOQs) for EE, NGMN, and NG and nore-
thindrone were established at 0.00247 ng/mL, 0.0198 ng/
mL, and 0.0203 ng/mL and 0.0936 ng/mL, respectively. 
The LLOQ for elagolix was established at 0.126 ng/mL for 
Fig. 1  Study design and proce-
dure notes. a Study 1; b Study 
2. QD once daily, PK pharma-
cokinetics
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standard range A (0.126–196 ng/mL) and 1.57 ng/mL for 
standard range B (1.57–2460 ng/mL).
2.3.2  Pharmacodynamic Samples
Serum hormone concentrations (E2, P, LH, FSH) were 
measured using College of American Pathologist (CAP)/
Clinical Laboratory Improvement Amendments (CLIA) 
assay methods at a central laboratory (Quest Diagnostics 
Nichols Institute, Valencia, CA, USA). LH and FSH were 
measured using the immunoassay methods, and E2 and P 
were measured using the LC–MS/MS methods. The LLOQ 
values were 0.5 IU/L for FSH, 0.2 IU/L for LH, 2 pg/mL for 
E2, and 0.32 nmol/L for P.
2.4  Statistical Analysis
2.4.1  Pharmacokinetics
The maximum observed plasma concentration (Cmax) and 
time to Cmax (peak time, Tmax), as well as the terminal phase 
elimination half-life and area under the plasma concentra-
tion–time curve (AUC) over the 24-h dosing interval (AUC 
24) were estimated for EE, NGMN, NG, norethindrone, and 
elagolix. Parameters were calculated using Phoenix™ Win-
Nonlin® version 6.3 (Pharsight Corporation, Mountain 
View, CA, USA) for both studies. Each woman served as 
their own control. A repeated measures analysis of variance 
(ANOVA) was performed to compare the PK of coadmin-
istration and oral contraceptives administered alone. The 
model included a fixed effect for regimen (oral contraceptive 
alone and oral contraceptives coadministered with elagolix); 
subjects were viewed as a random effect. Cmax and AUC 
were analyzed on the logarithmic scale. Within the frame-
work of ANOVA, the relative bioavailability assessments 
with point estimate and 90% confidence interval (CI) were 
provided for the ratios of EE, NGMN, NG, and norethin-
drone Cmax and AUC, to compare the coadministration of 
oral contraceptives with elagolix, versus alone.
2.4.2  Pharmacodynamics
Mean + standard deviation (SD) E2, P, LH, and FSH lev-
els were descriptively summarized in graphical format. In 
order to compare the overall concentrations and exposures 
for FSH and LH and E2 in both periods, the AUC values 
over period 1 on days 1–28 (AUC 1–28 days) and period 2 on 
days 57–84 (AUC 57–84 days) were calculated using Phoenix™ 
WinNonlin® version 6.3 (Pharsight Corporation) for both 
studies. The mean hormone AUC values were calculated and 
compared between period 1 (days 1–28) and period 2 (days 
57–84). Subjects who had the last PD samples collected 
before day 84 were excluded from E2, FSH, and LH AUC 
analysis. Additionally, the percentage of subjects with two 
consecutive P concentrations above 5 nmol/L were counted 
and assessed as markers for ovulation and compared between 
periods 1 and 2 [7].
2.4.3  Sample Size Calculations
For study 1, study size consideration was based on a com-
parison between day 21 (COC alone) and day 77 (COC in 
combination with elagolix) within the crossover ANOVA 
framework. Complete data from 26 subjects would provide 
approximately 80% power to detect the minimum detectable 
differences in AUC 24/Cmax for NGMN, NG, and EE.
For study 2, study size consideration was based on a 
comparison between day 7 (norethindrone alone) and day 
63 (norethindrone in combination with elagolix) within the 
crossover ANOVA framework. Complete data from 26 sub-
jects would provide approximately 82% power to detect a 
23% difference in the central value of norethindrone trough 
concentrations (Ctrough) between day 63 and day 7. The 
power calculations were performed using logarithmic trans-
formation. The calculation assumed the error term variance 
of 0.0967 for the natural logarithm of Ctrough.
Both studies planned to enroll 30 subjects to provide 
allowance for premature discontinuations, assuming a drop-
out rate of approximately 10%.
2.5  Safety and Tolerability
For both studies, adverse event (AE) monitoring and vital 
signs, physical examination, electrocardiogram, and labora-
tory test assessments were performed. Subjects who received 
at least one dose of study medication were included in the 
safety analyses. AEs were coded using the Medical Diction-
ary for Regulatory Activities (MedDRA) version 15.0.
The number and percentage of women having treatment-
emergent AEs (TEAEs) were tabulated by primary System 
Organ Class and MedDRA Preferred Term.
3  Results
3.1  Subject Dispositions
In study 1, 32 women were enrolled and 22 women com-
pleted the study. One woman was enrolled but was not dosed 
(positive drug screen). Nine women prematurely discontin-
ued: exclusionary medication (1), abnormal pap test (1), pos-
itive pregnancy test (1), AE of headache (1), and withdrew 
consent (5). Of note, the woman with a positive urine preg-
nancy test only received one dose of COC on day 1 of period 
1; screening serum and urine pregnancy tests were negative. 
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The analyses included 21 women for PK (one woman missed 
the intensive PK visit), 22 for PD, and 31 for safety.
In study 2, 34 women were enrolled and 26 women com-
pleted the study. Eight women prematurely discontinued 
for the following reasons: AEs of increased triglycerides (2, 
twin sisters) and hemoglobin decreased (1), positive drug 
screen (1), non-compliance (1), and withdrew consent (3). 
The analyses included 26 women for PK and PD, and 34 
for safety.
Table 1 summarizes the demographic characteristics.
4  Pharmacokinetics
In study 1, the PK parameters of EE, NGMN, and NG are 
presented in Table 2 and concentration–time profiles are 
presented in Fig. 2. The EE mean Cmax and AUC 24 values 
for period 2 were higher than those for period 1 (p ≤ 0.019; 
ANOVA). The NGMN Cmax and AUC 24 were slightly lower 
in period 2 than those in period 1 (p ≤ 0.043). For NG, no 
significant differences were observed between treatments 
(p ≥ 0.106). Relative bioavailability assessments for EE, 
NGMN, and NG are presented in Table 3. Elagolix increased 
EE Cmax and AUC by approximately 15% and 30%, respec-
tively, reduced NGMN Cmax and AUC by approximately 
Table 1  Summary of demographic characteristics for studies 1 and 2
Data are expressed as mean ± standard deviation (minimum–maxi-
mum) unless otherwise specified
a Two subjects were 49 years of age at the time consent was signed. 
All subjects were female
Characteristic Study 1 (n = 31) Study 2 (n = 34)
Age, years 31.0 ± 6.5 (20–43) 36.4 ± 8.5 (20–50)a
Weight, kg 66.5 ± 16.0 (44–106) 65.6 ± 12.8 (37–100)
Height, cm 161.4 ± 7.1 (150–175) 160.9 ± 6.1 (150–175)




Table 2  Pharmacokinetic 
parameters of ethinylestradiol/
NGMN/NG and elagolix in 
periods 1 and 2
Cmax, maximum plasma concentration, Tmax time to maximum plasma concentration, AUC 24 area under the 
concentration–time curve from time zero to 24 h, t½ terminal elimination half-life, QD once daily, NGMN 
norelgestromin, NG norgestrel, ANOVA analysis of variance
a Harmonic mean ± pseudo-standard deviation; evaluations of  t½ were based on statistical tests for β
b N = 20 for  t½ on day 77





Period 1, day 21 Period 2, day 77
(ethinylestradiol/norgestimate 0.035 
mg/0.25 mg QD alone) [n = 21]
(estradiol/norgestimate 0.035 mg/0.25 
mg QD + elagolix 150 mg QD) 
[n = 21]
Ethinylestradiol
Cmax (ng/mL) 0.168 ± 0.061 0.195 ± 0.076c
Tmax (h) 1.5 ± 0.5 1.9 ± 2.4
AUC 24 (ng·h/mL) 1.27 ± 0.56 1.65 ± 0.72c
t½a,b (h) 15.4 ± 5.7 14.2 ± 4.9
NGMN
Cmax (ng/mL) 2.29 ± 0.60 2.00 ± 0.51c
Tmax (h) 1.4 ± 0.3 1.4 ± 0.3
AUC 24 (ng·h/mL) 18.3 ± 4.8 15.5 ± 4.3c
t½a (h) 22.8 ± 7.3 20.9 ± 6.8
NG
Cmax (ng/mL) 3.02 ± 1.91 2.72 ± 1.54
Tmax (h) 2.7 ± 4.9 2.2 ± 2.5
AUC 24 (ng·h/mL) 51.6 ± 32.9 49.0 ± 30.8
t½a,d (h) 43.5 ± 24.6 43.5 ± 24.8
Elagolix
Cmax (ng/mL) – 504.4 ± 179.3
Tmax (h) – 1.1 ± 0.4
AUC 24 (ng·h/mL) – 1100.9 ± 392.6
t½a,d (h) – 3.7 ± 1.7
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Fig. 2  Pharmacokinetic profiles mean + standard deviation of triphasic OC alone and triphasic OC with elagolix (linear scale, n = 21). a Ethi-
nylestradiol; b NGMN; c NG; and d Elagolix (n = 20). OC oral contraceptive, NGMN norelgestromin, NG norgestrel
Table 3  Relative bioavailability and 90% CIs in study 1
Units for Cmax and AUC 24 central values are ng/mL and ng∙h/mL, respectively
Cmax maximum plasma concentration, AUC 24 area under the concentration–time curve from time zero to 24 h, NGMN norelgestromin, NG norg-
estrel, CI confidence interval, PK pharmacokinetic
a Antilogarithm of the least squares means for logarithms
b Antilogarithm of the difference (test minus reference) of the least squares means for logarithms
Regimens (test vs. reference) PK parameter Central  valuea Relative bioavailability
Test Reference Point  estimateb 90% CI
Ethinylestradiol
Ethinylestradiol/norgestimate + elagolix vs. ethinylestradiol/norgestimate 
alone
Cmax 0.181 0.157 1.15 1.066–1.248
AUC 24 1.50 1.16 1.30 1.186–1.416
NGMN
Ethinylestradiol/norgestimate + elagolix vs. ethinylestradiol/norgestimate 
alone
Cmax 1.93 2.21 0.872 0.781–0.973
AUC 24 14.9 17.6 0.847 0.782–0.918
NG
Ethinylestradiol/norgestimate + elagolix vs. ethinylestradiol/norgestimate 
alone
Cmax 2.16 2.44 0.886 0.784–1.002
AUC 24 36.1 39.1 0.923 0.840–1.013
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13% and 15%, respectively, and reduced NG by 11% and 
8%, respectively. The EE Cmax and NG AUC 24 90% CIs were 
within the ‘no-effect boundary’ of 80–125% [10].  
In study 2, the norethindrone PK parameters are shown 
in Table 4 and the concentration–time profiles are shown in 
Fig. 3. Other than an earlier mean Tmax value (p = 0.032), no 
other norethindrone PK parameters were different between 
the two periods.
Relative bioavailability assessments for EE, NGMN, 
and NG are presented in Table 5. Elagolix decreased nore-
thindrone Cmax and AUC by approximately 5% and 12%, 
respectively. The 90% CI for norethindrone Cmax was within 
the no-effect boundary, whereas the lower bound of the 
norethindrone AUC 24 90% CI extended slightly below 0.80 
(0.788) [10].
Elagolix PK parameters for both studies (Tables 2, 3) are 
consistent with previously observed parameters [5, 8].
4.1  Pharmacodynamic Changes
Figures 4 and 5 show the mean concentration–time profiles 
for FSH, LH, E2, and P in studies 1 and 2, respectively. In 
study 1, when elagolix was coadministered with COCs, the 
mean hormone exposure (assessed based on comparison of 
AUC values in periods 1 and 2; n = 14) for FSH, LH, and 
E2 appeared to be 31%, 38%, and 16% lower, respectively, 
compared with those observed with COCs alone. As an 
indirect marker of ovulation, 18% of women (4/22) had two 
consecutive ovulatory P concentrations > 5 nmol/L on days 
1–28 in period 1, and 14% of women (3/22) on days 57–84 
in period 2.
In study 2, when elagolix was coadministered with nore-
thindrone, the hormone exposure for FSH, LH, and P, was 
similar to those observed with norethindrone alone. FSH and 
LH concentrations were 10% higher and 8% lower (n = 19), 
respectively, with coadministration when compared with 
norethindrone alone. E2 concentrations appeared to be 32% 
lower (n = 19) when elagolix was coadministered with nore-
thindrone, compared with norethindrone alone. Sixty-one 
percent of women (16/26) had two consecutive ovulatory P 
concentrations on days 1–28 in period 1 and on days 57–84 
in period 2.
For both studies, the observed interindividual variabilities 
in hormone exposure (AUC) are overall larger than reported 
for PK exposure, which may be explained by the sparse hor-
mone sampling and large changes in hormone levels when 
ovulation occurred.
Table 4  Pharmacokinetic parameters of norethindrone
Cmax maximum plasma concentration, Tmax time to maximum plasma 
concentration, AUC 24 area under the concentration–time curve from 
time zero to 24  h, t½ terminal elimination half-life, QD once daily, 
ANOVA analysis of variance
a Harmonic mean ± pseudo-standard deviation; evaluations of t½ were 
based on statistical tests for β





Period 1 Period 2
(norethindrone 
0.35 mg QD alone) 
[n = 26]
(norethindrone 0.35 mg 
QD + elagolix 150 mg 
QD) [n = 26]
Norethindrone
Cmax (ng/mL) 2.76 ± 0.88 2.59 ± 0.76
Tmax (h) 1.67 ± 0.45 1.44 ± 0.32b
AUC 24 (ng·h/mL) 14.16 ± 5.89 12.30 ± 4.02
t½a (h) 7.85 ± 2.69 7.87 ± 3.51
Elagolix
Cmax (ng/mL) – 555.4 ± 254.6
Tmax (h) – 1.2 ± 0.4
AUC 24 (ng·h/mL) – 1215.1 ± 540.6
t½a (h) – 3.8 ± 1.4
Fig. 3  Pharmacokinetic profiles mean + standard deviation of the mini-pill alone and mini-pill with elagolix (linear scale, n = 26). a Norethin-
drone; b Elagolix
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4.2  Safety and Tolerability
In study 1, 10/31 (32.3%) women experienced at least one 
TEAE during period 1 (COC) and 15/25 (60.0%) women 
during period 2 (COC + elagolix). The most common 
TEAEs reported for two or more women during period 1, in 
order of decreasing frequency, were headache and upper res-
piratory tract infection (URTI), and headache, nausea, URTI, 
and vomiting in period 2. The percentage of TEAEs assessed 
by the investigator as possibly or probably related to COC 
or elagolix were 6.5% (period 1, COC), 16.0% (period 2, 
COC), and 24.0% (period 2, elagolix). The AEs in periods 1 
and 2 were assessed as mild or moderate by the investigator, 
except for one woman experiencing a single AE of tonsillitis 
streptococcal (period 1), which was assessed as severe.
In study 2, 17/31 (54.8%) women experienced at least one 
TEAE during period 2 (norethindrone + elagolix) compared 
with 12/34 (35.3%) women during period 1 (norethindrone). 
The most common TEAEs reported for two or more women 
in period 2, in order of decreasing frequency, were headache, 
Table 5  Relative bioavailability and 90% CIs in study 2
Units for Cmax and AUC 24 central values are ng/mL and ng∙h/mL, respectively
Cmax maximum plasma concentration, AUC 24 area under the concentration–time curve from time zero to 24 h, CIs confidence intervals, PK phar-
macokinetic
a Antilogarithm of the least squares means for logarithms
b Antilogarithm of the difference (test minus reference) of the least squares means for logarithms
Regimens (test vs. reference) PK parameter Central  valuea Relative bioavailability
Test Reference Point  estimateb 90% CI
Norethindrone
Norethindrone + elagolix vs. norethindrone alone Cmax 2.48 2.62 0.947 0.856−1.047
AUC 24 11.6 13.2 0.882 0.788−0.987
Fig. 4  Mean ± standard deviation concentration–time profiles after 
administration of triphasic OC alone and triphasic OC with elagolix 
in study 1 (linear scale, n = 22). Days 1–28, triphasic OC alone; days 
57–84, triphasic OC with elagolix. a FSH; b LH; c estradiol; d pro-
gesterone. FSH follicle-stimulating hormone, LH luteinizing hormone
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nausea, URTI, increase in blood triglycerides, influenza, and 
muscle spasms, and nausea, headache, breast tenderness, and 
uterine spasm in period 1. The percentage of TEAEs assessed 
by the investigator as possibly or probably related to nore-
thindrone or elagolix were 26.5% (period 1, norethindrone), 
19.4% (period 2, norethindrone), and 22.6% (period 2, elago-
lix). TEAEs were mostly assessed as mild to moderate for both 
drugs; one woman experienced a single AE (increase in blood 
triglycerides) assessed as severe during coadministration.
No deaths occurred during either study. No clinically sig-
nificant vital signs, electrocardiogram, or changes in labo-
ratory measurements were observed during study 1, and 
during study 2 all other changes were unremarkable. The 
regimens tested were generally well tolerated in both studies.
5  Discussion
Two DDI studies evaluated the effects of elagolix 150 mg 
once daily on COCs in study 1 or the progestin-only oral 
contraceptive in study 2. The PK results demonstrate that the 
administration of elagolix 150 mg once daily slightly reduced 
exposures of two progestins (norgestimate metabolites and 
norethindrone) by 8–15%. The small but not clinically rel-
evant reduction in progestin concentrations is attributed to 
effects on the metabolic pathway of progestins [11–13]. 
Although the specific enzymes involved in progestin metabo-
lism have not been well-defined, CYP3A4, CYP2B6, and uri-
dine 5ʹ-diphospho (UDP)-glucuronosyltransferases may play 
a role in the metabolism of norgestimate [14, 15], whereas 
CYP3A and CYP2C19 enzymes also contribute to the metab-
olism of norethindrone [16–18]. Consistent with previous 
findings where elagolix 150 mg once daily caused weak 
induction of CYP3A [8], this study demonstrated that elago-
lix 150 mg once daily causes a small or negligible induction 
of the metabolic pathways involved in progestin metabolism. 
The half-lives of the progestins were not altered by elagolix 
in this study, therefore the small impact by elagolix may be 
mostly at the level of the gastrointestinal tract.
Administration of elagolix 150 mg once daily resulted 
in a small increase in EE concentrations in study 1 (30%). 
CYP3A enzymes, sulfation (SULT1E1), and glucuronida-
tion (UGT1A1) have been reported to be involved in the 
metabolism of EE [19–23]. Two previous studies support 
that elagolix is a weak to moderate CYP3A inducer [1], 
which indicates that elagolix coadministration may result 
Fig. 5.  Mean ±  standard deviation concentration–time profiles after 
administration of norethindrone alone and norethindrone with elago-
lix in study 1 (linear scale, n = 26). Days 1–28, norethindrone alone; 
days 57–84, norethindrone with elagolix. a FSH; b LH; c estradiol; d 
progesterone. FSH follicle-stimulating hormone, LH luteinizing hor-
mone
 R. A. Feldman et al.
in slightly lower, not higher, EE concentrations [8, 24, 25]. 
Because elagolix is a P-gp inhibitor and caused increases 
in the exposure of the P-gp substrate digoxin [8], the small 
increase in EE exposures observed in this study may be 
attributed to inhibition of P-gp by elagolix and increase in 
the absorption of EE. This is also supported by in vitro evi-
dence suggesting that EE is a P-gp substrate [26].
Elagolix exposure and variability was comparable with 
other phase I studies at the 150 mg once-daily dose [5, 8, 
27]. Cross-study comparisons suggest that it does not appear 
that either contraceptive affected elagolix PK.
These studies also evaluated the impact of coadministra-
tion of elagolix 150 mg once daily on the PD of hormonal 
contraceptives. The studies demonstrate that coadministra-
tion of elagolix with hormonal oral contraceptives main-
tain the hormone suppressive profiles compared with oral 
contraceptives administered alone. Hormonal contracep-
tives inhibit ovulation by inhibiting LH and FSH [9], which 
then reduce E2 and P concentrations. Coadministration with 
elagolix resulted in similar or lower LH and FSH exposures, 
and ovulation rate (as assessed by P concentrations) did 
not appear to be impacted in both studies. Therefore, the 
coadministration of elagolix with hormonal contraceptives 
may offer similar contraceptive effects to hormonal contra-
ceptives administered alone. This is based on (1) small PK 
changes in progestin (≤ 15%) and EE exposure (32%); (2) 
similar or lower FSH, LH, and P PD profiles (with elagolix); 
and (3) additional E2 suppression from elagolix in addition 
to E2 suppression by hormonal contraceptives.
The overall safety and efficacy of the combinations of 
elagolix and hormonal oral contraceptives needs to be fur-
ther evaluated and confirmed in a larger study in women 
with endometriosis-associated pain. Future studies should 
determine if elagolix efficacy may be reduced when tak-
ing estrogen-containing contraceptives, and if the safety of 
coadministration is maintained given the small increase in 
EE concentrations that were observed in this study. The 30% 
increase in EE concentrations are considered small for oral 
contraceptives with low dose EE (< 25 μg); nevertheless, 
one may need to take into consideration oral contraceptives 
with a higher EE dose (> 25 μg).
The limitations of these studies include sparse hormone 
sampling, and elagolix was only tested at the 150 mg dose. 
Elagolix can be administered at the higher dose of 200 mg 
twice daily. A future study may evaluate the PK/PD at the 
higher elagolix dose.
6  Conclusion
Coadministration of elagolix with orally administered nore-
thindrone or combination hormonal contraceptives contain-
ing EE and norgestimate resulted in small changes in the PK 
of oral hormonal contraceptive components; elagolix PK do 
not appear to be affected. The hormonal PD effects of oral 
contraceptives were not negatively impacted by coadminis-
tration with elagolix.
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